Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026GlobeNewsWire · 6 days ago
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity DeficiencyGlobeNewsWire · Sep 25, 2026
Calidi Biotherapeutics Announces $1.2 Million Registered Direct OfferingGlobeNewsWire · Sep 17, 2026
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 8, 2026
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewsWire · Aug 13, 2026
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development ConferenceGlobeNewsWire · Jul 27, 2026Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | – | -$2.94 | |
| Mar 30, 2026 | – | -$6.88 | |
| Mar 27, 2026 | -$24.96 | -$9.12 | Beat |
| Nov 11, 2025 | -$26.88 | -$35.36 | Miss |
| Aug 12, 2025 | -$30.72 | -$31.84 | Miss |
| May 13, 2025 | -$28.80 | -$34.56 | Miss |